Following a directed appraisal
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA489: Vismodegib for treating basal cell carcinoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | vismodegib (Erivedge®) | ||
| Formulation | 150 mg capsule | ||
| Reference number | 1037 | ||
| Indication | Treatment of adult patients with symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Directed | ||
| Status | Superseded | ||
| Advice number | 0917 | ||
| NMG meeting date | 11/01/2017 | ||
| AWMSG meeting date | 26/04/2017 | ||
| Date of issue | 11/09/2017 | ||
| NICE guidance | |||